Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : BigHat Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lonza’s Synaffix Collaborates with Bighat Biosciences for ML-designed ADC
Details : BigHat will combine Synaffix technology with its world-class ML antibody design platform for the development of a new ADC pipeline program.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 04, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : BigHat Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IBI-343
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.
Brand Name : IBI-343
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 06, 2023
Lead Product(s) : IBI-343
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sotio
Deal Size : $740.0 million
Deal Type : Licensing Agreement
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
Details : Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sotio
Deal Size : $740.0 million
Deal Type : Licensing Agreement
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : MacroGenics
Deal Size : $2,200.0 million
Deal Type : Licensing Agreement
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Details : Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-cla...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : MacroGenics
Deal Size : $2,200.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Chong Kun Dang Pharm
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
Details : Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Chong Kun Dang Pharm
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Amgen Inc
Deal Size : $2,000.0 million
Deal Type : Licensing Agreement
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
Details : Amgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one Antibody Drug Conjugate (ADC) program.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Amgen Inc
Deal Size : $2,000.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Study Phase : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Highest Development Status : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Study Phase : Preclinical
Sponsor : Emergence Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal
Details : Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $360.0 million
September 06, 2022
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Preclinical
Sponsor : Emergence Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate Therapeutic
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kyowa Kirin
Deal Size : $176.0 million
Deal Type : Licensing Agreement
Details : The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $5.0 million
June 30, 2022
Lead Product(s) : Antibody-drug Conjugate Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kyowa Kirin
Deal Size : $176.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?